IL34 and renal cell carcinoma: ,48 Taken together, our results reveal the involvement of the IL34-CSF1R axis in the RCC tumor vasculature and immunity through the regulation of MD-TAMs biology and suggest that blockade of the IL34-CSF1R axis could be used to improve RCC therapy.